Nandrolone

Nephrosis or nephrotic phase of nephritis, cardiac failure; male patients with carcinoma of breast or prostate; porphyria, hepatic disease with impaired bilirubin excretion. Pregnancy and lactation. Contraindications may vary among countries and between individual products (refer to specific product guidelines).

Patient with CV disease, history of MI or CAD; diabetes mellitus, conditions influenced by oedema (e.g. migraine, seizure disorder), benign prostatic hyperplasia. Renal impairment. Elderly.

Significant: Dyslipidaemia; hypercalcaemia or hypercalciuria (particularly in patients with prolonged immobilisation or cancer); sodium and fluid retention, drug abuse or dependence; signs of virilisation including mild acne, facial hair changes, and hoarse voice.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reaction, oedema.
Hepatobiliary disorders: Peliosis hepatitis, liver tumours.
Investigations: Abnormal hepatic function, increased haemoglobin.
Renal and urinary disorders: Reduced urine flow.
Reproductive system and breast disorders: Enlarged clitoris, increased libido.
Skin and subcutaneous tissue disorders: Pruritus.
Vascular disorders: Hypertension.

IM/Parenteral: X

Monitor LFTs periodically; electrolytes, haemoglobin, haematocrit, lipid panel, glucose (in diabetic patients), serum and urinary calcium. Assess for signs of virilisation in women. Perform PSA and digital rectal exam in male patients before treatment initiation, every 3 months during the 1st year, and annually thereafter.

May enhance oedema formation with ACTH or corticosteroids. High doses of nandrolone may increase the anticoagulant effects of coumarin-type agents. May enhance the hypoglycaemic effects of antidiabetic drugs. Nandrolone may increase the erythropoiesis-stimulatory effect of erythropoiesis-stimulating agents.

May alter metyrapone test. May reduce thyroxine-binding globulin leading to reduced total T4 and increased resin uptake of T3 and T4.

Description:
Mechanism of Action: Nandrolone is an anabolic steroid that promotes positive calcium balance and bone mass density. It helps promote protein anabolism and inhibit protein catabolism through its nitrogen-sparing effect.
Duration: Approx 3 weeks.
Pharmacokinetics:
Absorption: Time to peak serum concentration: 2.4-3.6 days.
Metabolism: Metabolised in the liver.
Excretion: Via urine (as metabolites). Elimination half-life: Approx 6 days (range: 5-15 days).

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 9904, Nandrolone. https://pubchem.ncbi.nlm.nih.gov/compound/Nandrolone. Accessed June 26, 2025.

Store below 30°C. Protect from light.

Anabolic Agents

A14AB01 - nandrolone ; Belongs to the class of estren derivative anabolic steroids used as systemic anabolic agents.

Brayfield A, Cadart C (eds). Nandrolone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/06/2025.

Deca Durabolin 50 mg/mL (Aspen Pharma Trading Limited). MHRA. https://products.mhra.gov.uk. Accessed 02/06/2025.

Nandrolone. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 02/06/2025.